Access to abrocitinib for severe eczema not helped by other treatments
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This program provides access to an investigational medicine called abrocitinib (a pill for eczema) for a single patient with severe eczema that hasn't improved with other treatments. It is meant for people who have no other good options and cannot participate in a standard clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have severe eczema (also called atopic dermatitis) that is not well controlled.
- You must have tried other available treatments for eczema, but they haven't worked well enough.
- This is an individual patient program, meaning it's for one person at a time, not a large study.
- The study is for patients who are not able to join a regular clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a daily pill, abrocitinib, to see if it safely reduces severe eczema (atopic dermatitis) in children aged 2 to under 6 years. It may help when creams or other treatments haven't worked well enough.
This study tests how well abrocitinib (a prescription medicine) works for adults with moderate to severe atopic dermatitis (atopic eczema). You may join if you meet the study’s health and consent requirements and your doctor believes abrocitinib is an appropriate option for you.
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
This trial tests a daily pill called Abrocitinib to see if it can help children ages 6 to 11 with moderate-to-severe eczema that hasn't gotten better with creams or ointments. Eczema (also called atopic dermatitis) causes itchy, red skin, and this medicine might calm the immune response to reduce itching and rashes.
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
This study tests whether gradually lowering the dose of abrocitinib can keep your eczema under control while reducing side effects. It is for people with moderate-to-severe eczema who have already been on abrocitinib 200 mg daily for at least 3 months and whose skin is currently well controlled.
Hear when a new Severe Uncontrolled Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.